## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.6% below STRENGTH zone (4.0-10.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($554.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. 10 Best Dividend Stocks Hedge Funds Are Buying**
- Source: Insider Monkey | 20251130T120500 | Bullish | Relevance: 99%
- This article identifies Thermo Fisher Scientific Inc. (NYSE: TMO) as one of the best dividend stocks favored by hedge funds. It details the company's recent Euro-denominated note offering worth €2.1 billion to fund corporate expenditures and debt repayment, and highlights a "Buy" rating from Stifel Nicolaus with a $583 price target. Thermo Fisher Scientific is a Massachusetts-based company specializing in life sciences products, lab equipment, and biopharma services.

**2. Thermo Fisher Scientific (TMO) Stock on 1 December 2025: HSBC Upgrade, Insider Moves, Buyback and 2026–2030 Forecasts**
- Source: ts2.tech | 20251201T190803 | Somewhat-Bullish | Relevance: 99%
- This article analyzes Thermo Fisher Scientific (TMO) stock as of December 1, 2025, detailing an HSBC upgrade to "Buy," recent insider transactions, institutional investor moves, and a $5 billion share repurchase authorization. It also covers the company's Q3 2025 earnings beat, the strategic acquisition of Clario, and various analyst and algorithmic forecasts for its future performance through 2030. The piece concludes with a balanced view of the bullish and cautionary factors for TMO stock.

**3. Thermo Fisher (TMO) Raises €2.1 Billion Through Floating and Fixed-Rate Senior Notes**
- Source: MSN | 20251202T070743 | Somewhat-Bullish | Relevance: 99%
- Thermo Fisher Scientific Inc. (NYSE: TMO) has successfully completed an offering of €2.1 billion in euro-denominated senior notes. The offering included both floating-rate notes due 2026 and fixed-rate notes due 2030, with interest rates of EURIBOR plus 0.450% and 3.625% respectively. The funds raised are intended for general corporate purposes, including the repayment of existing debt.

**4. Thermo Fisher Scientific Stock: Is TMO Outperforming the Health Care Sector?**
- Source: MSN | 20251130T183645 | Neutral | Relevance: 98%
- This article examines whether Thermo Fisher Scientific (TMO) is outperforming its sector peers. It compares TMO's year-to-date return of +5.92% to the S&P 500's +7.21% and the Medical sector's +5.31%, suggesting TMO is outperforming its sector but lagging the broader market. Key financial metrics like earnings growth, cash flow, and debt-to-equity are highlighted to provide a fundamental perspective on the company.

**5. Thermo Fisher Scientific (TMO) Stock on December 2, 2025: Price Action, HSBC Upgrade, New Debt Deal and 2026–2030 Forecasts**
- Source: ts2.tech | 20251202T185537 | Bullish | Relevance: 98%
- Thermo Fisher Scientific (TMO) is experiencing significant activity on December 2, 2025, including a stock price near its 52-week high, a new €2.1 billion bond deal, a $5 billion share repurchase authorization, and an HSBC price target upgrade to $670. The company's strong Q3 2025 earnings, strategic acquisitions like Clario, and partnerships with OpenAI for AI integration are driving positive analyst sentiment, though valuation risks and mixed algorithmic forecasts suggest varying long-term outlooks.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $42M sold (14 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $215.6B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 23.5 |
| Current P/E | 25.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.4% to -1.6% (-6.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.6pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.54), momentum weakening. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.60% (CS: 39) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | -1.54 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.208x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $580.37
- **Stop Loss:** $554.09 (4.5% risk)
- **Target:** $606.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $22,054.06
- **Portfolio %:** 22.05%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*